AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-84. (canceled)

85. (currently amended) A method for activating a $T\gamma 9\delta 2$ ~~lymphocytes~~ lymphocyte in vitro, comprising:

contacting a $T\gamma 9\delta 2$ lymphocyte with an effective amount of a compound comprising at least one phosphoepoxide group, said compound having ~~the following~~ a formula selected from the group consisting of

(a) a compound having the following formula:



(2)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20[[.]];

(b) a compound having the following formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20; and.

(c) a compound having the following formula:



(5)

wherein R1 is selected from among $-CH_3$ and CH_2CH_3,

Cat^+ is a cation, and

n is an integer between 2 and 20, and

R2 is a biomolecule.

86. (currently amended) The method according to claim 85, wherein said compound is brought into contact with a $T\gamma9\delta2$ ~~lymphocytes~~ lymphocyte in the presence of a T lymphocyte growth factor.

87. (previously presented) The method according to claim 85, wherein said T lymphocyte growth factor is IL-2.

88. (currently amended) The method according to claim 85, wherein said compound is introduced [[in]] into a medium containing said Tγ9δ2 lymphocytes and cells.

89. (currently amended) The method according to claim 85, wherein said compound and said Tγ9δ2 ~~lymphocytes~~ lymphocyte are introduced [[in]] into a medium~~, wherein said medium~~ that allows for T lymphocyte growth.

90-93. (canceled)

94. (currently amended) The method according to claim 88, wherein said ~~medium is an extra corporeal medium~~ method for activating a Tγ9δ2 lymphocyte is *in vitro*.

95. (currently amended) The method according to claim 88, further comprising topically administering said compound [[on]] to said medium.

96. (currently amended) A compound of the formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20.

97. (currently amended) A compound of the formula:



(5)

wherein R1 is selected from among $-CH_3$ and CH_2CH_3,

Cat^+ is a cation,

n is an integer between 2 and 20, and

R2 is a ~~substituent~~ biomolecule. ~~selected from the group consisting of:~~

~~a) a compound allowing formation of a compound of the formula:~~



(14)

~~which by reaction with a halogen X_2 in the presence of water leads to an intermediate compound:~~



(15)

~~the latter, in basic medium leading to compound (5), and chosen from:~~

~~i) a compound R2-O-Y which is reactive with the terminal phosphate of a compound of formula:~~



(11)

~~ii) a compound R2-O-PPP which is reactive with a compound of formula:~~



(8)

~~-PPP is a triphosphate group,~~

~~X, a halogen of an halogenure, and~~

~~-O-Y, a leaving group;~~

~~b) a compound R2-O-PPP which is reactive with a compound of the formula:~~



(13)

~~to obtain compound (5);~~

~~c) a trimetaphosphate~~



~~which is reactive with a compound of the formula:~~



(20)

~~in order to obtain compound (5).~~

98. (currently amended) A composition comprising an excipient and a compound that can activate Tγ9δ2 lymphocyte, wherein said ~~composition~~ compound is selected from the group consisting of:

a) a compound of the formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2-CH_3$,

Cat^+ is a cation,

n is an integer between 2 and 20; and

b) a compound of the formula:

a compound of the formula:



(5)

according to claim 97.

99. (previously presented) The composition according to claim 98, further comprising a pharmaceutically acceptable excipient.

100. (canceled)

101. (currently amended) The composition according to claim 98, wherein said composition is adapted to be ~~administered to a primate by a general route~~ delivered to a primate by a systemic administration.

102. (previously presented) The composition according to claim 98, wherein said composition is adapted to be administered parenterally into a peripheral bloodstream of a primate.

103. (previously presented) The composition according to claim 98, wherein said compound is diluted in a sterile phosphate buffer at ph7.

104. (currently amended) The composition according to claim 98, wherein said composition is ~~adapted to be~~ in the form of a composition that can be topically administered.

105. (previously presented) The composition according to claim 98, further comprising primate Tγ9δ2 lymphocytes.

106. (previously presented) The composition according to claim 98, further comprising a T lymphocyte growth factor.

107. (currently amended) A method for activating Tγ9δ2 lymphocytes in a primate, comprising <u>directly</u> administering to said primate an effective amount of a compound selected from the group consisting of:

a) a compound of the formula:



(2)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat+ is a cation,

n is an integer between 2 and 20;

b) a compound of the formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation,

n is an integer between 2 and 20; and

c) a compound of the formula:



(5)

according to claim 97.

108. (previously presented) The method according to claim 107, further comprising topically administering said compound.

109. (previously presented) The method according to claim 107, further comprising administering said compound into a peripheral bloodstream of a primate.

110. (previously presented) The method according to claim 107, further comprising parenterally administering said compound into a peripheral bloodstream of a primate.

111. (previously presented) The method according to claim 107, wherein said primate suffers from cancer.

112. (previously presented) The method according to claim 107, wherein said primate suffers from a parasitic condition.

113. (previously presented) The method according to claim 107, wherein said primate suffers from a disease selected from the group consisting of cancers, parasitic conditions and pathological immunodeficiency syndromes.

114. (currently amended) A method for activating Tγ9δ2 lymphocytes in a vertebrate, comprising <u>directly</u> administering to said vertebrate an effective amount of compound selected from the group consisting of:

a) a compound of the formula:



(2)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat+ is a cation,

n is an integer between 2 and 20;

b) a compound of the formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation,

n is an integer between 2 and 20; and

(c) a compound of the formula:



(5)

according to claim 97.

115. (canceled)

116. (currently amended) A compound of the formula:



(5)

wherein R1 is selected from among $-CH_3$ and $-CH_2-CH_3$,

Cat^+ is a cation,

n is an integer between 2 and 20, and

R2 is ~~an organic or inorganic substituent~~ selected from the group consisting of a nucleoside and a phosphoepoxide.

117. (currently amended) A composition comprising <u>an excipient and</u> a compound that can activate Tγ9δ2 lymphocytes, wherein said compound is selected from the group consisting of

[[-]] <u>a)</u> a compound of the formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, <u>and</u>

n is an integer between 2 and 20,

and

[[-]] b) a compound of the formula:



(5)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20,

and R2 is ~~an in organic or inorganic substituent~~ selected from the group consisting of a nucleoside and a phosphoepoxide.

118. (currently amended) A method for activating Tγ9δ2 ~~lymphocytes~~ lymphocyte, comprising:

contacting a Tγ9δ2 lymphocyte with an effective amount of a compound having a formula selected from the group consisting of

a)



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2-CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20; and

b)



(5)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation,

n is an integer between 2 and 20, and

R2 is a substituent selected from the group consisting of a nucleoside and a phosphoepoxide.

119. (new) A method for activating a Tγ9δ2 lymphocyte *in vitro*, comprising:

contacting a Tγ9δ2 lymphocyte with an effective amount of a compound comprising at least one phosphoepoxide group, said compound having a formula selected from the group consisting of

(a) a compound having the following formula:



(2)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20;

(b) a compound having the following formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20; and

(c) a compound having the following formula:



(5)

wherein R1 is selected from among $-CH_3$ and CH_2CH_3,

Cat^+ is a cation, and

n is an integer between 2 and 20, and

R2 is a biomolecule.